NDAORAL-21TABLET
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LOESTRIN 21 1/20 (ethinyl estradiol; norethindrone acetate) by Teva. Approved for pregnancy. First approved in 1976.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOESTRIN 21 1/20 is an oral contraceptive tablet combining ethinyl estradiol and norethindrone acetate, indicated for pregnancy prevention. It is a small-molecule combination hormone therapy that operates on a 21-day active dosing cycle. This product represents a legacy oral contraceptive with established clinical utility in women's health.
LOE Approaching
As LOE approaches, the brand team is likely consolidating resources and transitioning focus to generic conversion management and retained-value oral contraceptive portfolio optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on LOESTRIN 21 1/20 as LOE approaches requires expertise in defensive brand strategy, generic conversion, and market access navigation rather than growth-focused innovation. This career path suits professionals skilled in lifecycle management, managed care negotiations, and portfolio optimization in a declining-revenue environment.
Brand Manager
Worked on LOESTRIN 21 1/20 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.